A new service for brain injury survivors in the Scottish Borders has been launched following a £165,000 funding boost from the National Lottery Community Fund. Dynamic Community Fusion (DCF), a Galashiels-based social enterprise, has been awarded two years of funding to deliver the new Reconnect with Confidence programme for people living with brain injuries or…
Study to investigate the efficacy of opicapone in early-stage Parkinson’s disease (PD)
The design for a new phase III, double-blind, randomised trial for opicapone has been presented for the first time at the European Academy of Neurology (EAN) congress. Around 50% of patients with PD experience some degree of motor complications within 2–5 years of starting L-dopa/DDCI therapy and almost all develop such symptoms after 10 years…
Call for improved brain injury knowledge in social workers
UKABIF (UK Acquired Brain Injury Forum) is calling for social workers to be trained and informed around acquired brain injuries following a review into the death of a Brighton man. A review into the death of 42 year old ‘James’, who had an acquired brain injury (ABI), has found the current safeguarding system to be…
FDA Grants Accelerated Approval for Alzheimer’s Drug aducanumab
From www.fda.gov On June 8th, the US Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments. Accelerated approval can be based on…
Indoor way-finder launched at Chelsea & Westminster Hospital NHS Foundation Trust
BuzzStreets and Chelsea & Westminster Hospital NHS Foundation Trust are launching a unique indoor way-finder for hospitals to help patients and their families navigate their way around more easily, reduce staff time spent giving directions, help ensure patients arrive on time for appointments, reduce stress, and minimise traffic in the corridors. Research has shown that…
EC approves PONVORY (ponesimod)
European Commission approves PONVORYTM ▼ (ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features The pivotal Phase 3 OPTIMUM trial showed treatment with ponesimod led to a 30.5 percent reduction in annual relapse rate (p<0.001) vs. treatment with teriflunomide, an…
PhD Opportunity: Computer games to support arm rehabilitation after stroke
Background Stroke is one of the most common causes of disability across the world. Up to 80% of acute stroke patients experience loss of arm function, which affects quality of life. Arm impairment often persists after rehabilitation has ceased. Recovery may be optimised by intensive functional training, but this can be difficult after stroke e.g….
Consistency in migraine days over course of Ajovy®
Analysis of consistency in migraine days over the course of a dosing regimen for AJOVY® (fremanezumab-vfrm) Injection published in Headache – Analysis assessed migraine days at the beginning and end of quarterly and monthly dosing intervals Results from a post hoc analysis of a long-term, open-label extension study assessing migraine days at the beginning and…
Find ACNR articles in EuropePMC/PubMed
We have recently added the article Hallucinations in Parkinson’s disease to EuropePMC on behalf of authors Rimona Weil and Suzanne Reeves. Is your work supported by funders on this list? If you write about your work for ACNR, we can add your article to EuropePMC with no charges for you or your institution. Contact the…
